lap easiest sale comp model cc revenu growth
line compani guidanc roughli report revenu
ep forecast respect mirror street
estim believ perform keep path achiev sale
ep guidanc along consensu project
top line compani expect sale growth report
basi approxim cc oper basi compar prior
revenu guidanc report growth cc growth oper
growth respect cc sale growth guidanc divis renal
vs previous lsd increas vs lsd
declin previous advanc surgeri hsd increas vs previous lastli
project ep rang vs previous
revis project wake report forecast cc growth
bp prior estim chang reflect dynam
compani outlin weve lower renal sale expect rais
sale assumpt advanc surgeri report revenu
estim shi street consensu ep
forecast match street project
estim guidanc street assumpt
compani forecast sale growth report basi growth
roughli cc oper basi set ep guidanc
model report revenu growth cc growth
account guidanc fx impact report revenu ep forecast
respect mirror street estim note
compani lap softest sale comp pleas see figur
page detail project
lower expect renal off-set pharma advanc surgeri
recent reduc renal cc sale growth estim
latter match lower guidanc
strength pd therapi continu counterbal impact
strateg exit bloodlin busi revaclear dialyz recal associ suppli
constraint meanwhil show momentum advanc
surgeri hospit pharmaci compound servic recent inject
launch eas headwind gener competit brevibloc
cyclophosphamid full year manag project lsd cc sale growth
increas lsd declin previous impli slight deceler
cc growth shown cc pharmaceut sale growth assumpt
lastli advanc surgeri sale
benefit suppli problem surgiflo product say carri
two month upsid assumpt rais cc
sale growth forecast hsd increas previous project advanc
surgeri cc sale growth
believ surgiflo return histor sale level take longer guidanc
presum surgiflo began ship earli last month accord check
pleas see page report import disclosur
corpor split posit better focu deliv margin expans
top- bottom-lin growth long term margin progress made
recent year commend howev compani hamper low
single-digit top-lin growth trajectori time medic devic peer routin
gener revenu growth regularli reach high single-digit growth
rate think capabl manag team well balanc sheet
capac pursu higher-yield sale growth opportun via acquisit nevertheless
rate stock market perform believ attract long-term high-
growth revenu driver still larg unidentifi despit compani average-to-
focus support compani
achiev sale
oper cash flow track grow
expect
sale growth exce
oper basi ahead schedul
pipelin opportun acquisit
om expans come
pipelin fail deliv
 fail produc new top-lin
diversifi global healthcar compani product use hospit dialysi
clinic nurs home rehabilit center research laboratori patient home
compani organ six divis renal medic deliveri
nutrit advanc surgeri acut therapi year undergon
major structur chang includ acquir gambro enhanc renal
busi spin bioscienc divis baxalta streamlin
oper transform given work progress statu new
manag team begun method address compani significantli
improv margin profil recent year continu target acceler top-lin growth
opportun accret current margin
compani report thomson eikon cowen compani
thomson one cowen compani compani file bax setup neutral outlook vs consensu guidancecowen revenu estim consensu revenu estim cowen ep estim consensu ep estim model cc revenu growth line compani guidanc roughli report revenu ep forecast respect mirror street estim bax guidanc call report revenu ep bracket project street oper margin cowen estim consensu ww oper ex end decemb end decemb return dialyz plant full capac year-end increment expens year tailwindcontinu oper expens control support bp oper margin leverag cowen project bp cowen
compani report thomson eikon cowen compani
thomson one cowen compani compani file renal setup neutral outlook vs streetcowen revenu estim ccconsensu revenu estim cc growth model cc sale growth easiest comp full-year cc sale growth forecast match compani guidanc cc growth headwindsstrateg decis exit in-cent hd busi impact year recal temporari suppli constraint associ revacleardialyz impact less project total year tailwind increas patient volum periton dialysisearly-stag plan american kidney health initiativeeasiest sale comp year oper ex ww oper ex end decemb end decemb cowen
compani report thomson eikon cowen compani
thomson one cowen compani compani file medic deliveri setup neutral outlook vs streetcowen revenu estim ccconsensu revenu estim cc growth model cc sale growth full-year cc sale growth forecast mirror compani guidanc cc growth headwindsspik demand larg volum iv solut mostli larg decreas continu uptak new infus pump spectrum iq evo iq select intern market relat disposablesincreas sale mini-bag larg volum iv solut oper ex ww oper ex end decemb end decemb cowen
compani report thomson eikon cowen compani
thomson one cowen compani compani file pharmaceut setup neutral outlook vs streetcowen revenu estim ccconsensu revenu estim lsd cc increas model cc sale growth full-year cc sale growth forecast larg match compani guidanc low single-digit cc increas headwindsrevers normal perform compound outsid impact gener competit brevibloc cyclophosphamid cycloi includ bax cc growth calcul tailwind solid momentum cc growth oper ex cyclo shown strong intern sale includ gener injectablesnew product launch myxredlin approv fda oper ex ww oper ex end decemb end decemb cowen
compani report thomson eikon cowen compani
thomson one cowen compani compani file clinic nutrit setup neutral outlook vs streetcowen revenu estim ccconsensu revenu estim cc growth model cc sale growth full-year cc sale growth forecast line compani guidanc cc growth headwindscontinu challeng fromrec hurricane-rel suppli constraintswork provid whove recent adapt suppli constraint delay start parenter nutrit and/or reduc patient dosagemorebroadli workingtoeducateprovid onthebenefitsof parenter nutrit gradual effort requir year gain tractiontailwind on-going launch new product includ olimel high protein formul finomel triple-chamb bag fish oilfairli easi comp oper ex ww oper ex end decemb end decemb cowen
compani report thomson eikon cowen compani
thomson one cowen compani compani file advanc surgeri setup out-performance vs streetcowen revenu estim ccconsensu revenu estim hsd cc increas model cc sale growth full-year cc sale growth forecast exce compani guidanc high single-digit cc increas headwindsongo difficult comp due signific histor growth rate reach high teenstailwind continu demand bax flosealand recothromin begin recov suppli constraint surgiflothat neg impact product earli oper ex ww oper ex end decemb end decemb cowen
compani report thomson eikon cowen compani
thomson one cowen compani compani file acut therapi setup mostli streetcowen revenu estim ccconsensu revenu estim cc growth model cc sale growth full-year cc sale growth forecast exce compani guidanc cc growth headwindsdifficult comp due high histor growth ratestailwind on-going roll-out prismaxnext-gener technolog crrt therapeut plasma exchangenew product launch oper ex ww oper ex end decemb end decemb cowen
figur incom statement forecast vs consensu guidanc mm
compani report thomson eikon cowen compani
good gross gross net interest expens expens total expens incom incom tax incom tax incom oper ex intang restructur non-recur gain incom non-controlling inc inc oper ex-intang restructur non-recur gain share estim cowen
compani report thomson eikon cowen compani
compani report thomson eikon cowen compani
year end decemb end decemb end decemb good gross gross net interest expens expens total expens incom incom tax incom tax incom oper ex intang restructur non-recur gain incom non-controlling intang amort inc inc oper ex-intang oper ep includ intang restructur non-recur gain share per cowen
compani report thomson eikon cowen compani
good gross gross net interest expens expens total expens incom incom tax incom tax incom oper ex-intang oper ex-intang share analysisgross analysistot incom per share cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
competit dynam global potenti regulatori delay potenti delay
time product launch emerg develop market econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend share repurchas fluctuat foreign exchang rate
compani specif risk includ impact long-act factor viii agent
global share advat franchis limit increas plasma fraction
capac ig franchis time regulatori approv hyq line-extens
bioscienc product develop realiz synergi impact margin
gambro acquisit acquisit exposur emerg market
